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Cisplatin and taxol activate different signal pathways regulating cellular
injury-induced expression of GADDJ53
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Summary Signal transduction pathways activated by injury play a central role in coordinating the cellular
responses that determine whether a cell survives or dies. GADD153 expression increases markedly in response
to some types of cellular injury and the product of this gene causes cell cycle arrest. Using induction of
GADD153 as a model, we have investigated the activation of the cellular injury response after treatment with
taxol and cisplatin (cDDP). Activation of the GADD153 promoter coupled to the luciferase gene and
transfected into human ovarian carcinoma 2008 cells correlated well with the increase in endogenous
GADD153 mRNA after treatment with taxol but not after treatment with cDDP. Following treatment with
cDDP, the increase in endogenous GADD153 mRNA was 10-fold greater than the increase in GADDS53
promoter activity. Likewise, at equitoxic levels of exposure (IC80), cDDP produced a 5-fold greater increase in
endogenous GADD153 mRNA than taxol. The tyrosine kinase inhibitor tyrphostin B46 had no significant
effect on the ability of taxol to activate the GADDJ53 promoter, but inhibited activation of the GADD153
promoter by cDDP in a concentration-dependent manner. Tyrphostin B46 synergistically enhanced the
cytotoxicity of cisplatin; however, the same exposure had no significant effect on the cytotoxicity of taxol. We
conclude that (1) taxol and cDDP activate GADD153 promoter activity through different mechanisms; (2) the
signal transduction pathway mediating induction by cDDP involves a tyrosine kinase inhibitable by tyrphostin
B46; and (3) that inhibition of this signal transduction pathway by tyrphostin synergistically enhances cDDP
toxicity.
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Treatment of cells with chemotherapeutic agents results in
the induction of a number of 'damage response' genes. In
bacteria, rec A plays a central role in activating the SOS
damage response pathway (Walker, 1985). In yeast, ongoing
work has resulted in the discovery of a large number of genes
that are involved in the control of cell cycle arrest following
genotoxic injury, and in the detection and repair of DNA
adducts (Weinert and Hartwell, 1988; Rowley et al., 1992). In
mammalian cells, the responses to cellular injury and the
signal transduction pathways that control these responses are
less well understood. It is clear, however, that a large number
of genes are transcriptionally activated following cell cycle
arrest produced by growth factor deficiency or DNA damage
(reviewed in Holbrook and Fornace, 1991).
Most of the transcripts identified so far that are increased
during the cellular injury response are also inducible by
12-0-tetradecanoyl phorbol-13-acetate (TPA), suggesting the
participation of a phorbol ester response element. GADD153
is one of the cellular injury response genes that is not trans-
criptionally activated by TPA (Fornace et al., 1989).
GADD153 was originally cloned by hybridisation subtraction
of mRNA from UV-treated CHO cells (Fornace et al., 1988).
It is one of a family of genes that is coordinately regulated
by agents that induce cellular injury through growth arrest or
DNA damage (Fornace et al., 1989). GADD153 is highly
conserved in mammalian species; the hamster cDNA shares
78% nucleotide sequence identity with the human cDNA
(Park et al., 1992) and> 85% with the mouse cDNA
homologue (Ron and Habener, 1992). Although the function
of GADD153 in the cellular injury response is unknown, it
may be a modulator of the transcription factors C/EBP and
LAP. Ron and Habener (1992) cloned CHOP-10, the mouse
homologue of GADD153, by identifying proteins that could
dimerise with C/EBP or LAP but could not bind to the
cytokine-responsive enhancer element APRE (acute-phase
responsive element). They found that CHOP-10 was localised
to the nucleus and co-immumoprecipitated with LAP. They
also found that overexpression of CHOP-10 inhibited the
activation of an APRE-driven luciferase construct.
Although GADD153 is not induced by TPA, it is induced
by a variety of agents that cause cellular injury. These in-
clude UV light, serum starvation, media depletion
(Fornace et al., 1989), cysteine conjugates, dithiothreitol
(Chen et al., 1992), terminal differentiation (in some cases)
(Fornace et al., 1992), hypoxia (Price and Calderwood, 1992)
and various chemotherapeutic drugs and alkylating agents
(Luethy and Holbrook, 1992, 1994). We have shown that
treatment with the chemotherapeutic agent cDDP increases
GADD153 mRNA levels in 2008 ovarian carcinoma cells
both when grown in vitro and as xenografts in nude mice
(Gately et al., 1994). However, neither the signal transduc-
tion pathways nor the biochemical mechanisms that are res-
ponsible for the induction of GADD153 by cDDP have been
identified. Barlett et al. (1992) postulated that the induction
is dependent on an increase in intracellular calcium, but the
specific transcription factors involved remain to be eluci-
dated.
Recently it was reported (Aman et al., 1992; Crozat et al.,
1993) that GADD153 is involved in the oncogenesis of
human myxoid liposarcomas. It was demonstrated that the
characteristic chromosomal translocation found in this
tumour type creates a fusion protein of GADD153 and a
previously unreported RNA-binding protein (named TLS for
translocated in liposarcoma; Crozat et al., 1993). This fusion
protein contains the DNA-binding and leucine-zipper dom-
ains of the GADD153 protein fused to a domain in TLS that
has a glycine-rich region similar to that of the transcription
factor Spl. It was hypothesised that this translocation
changes the effect of GADD153/CHOP-10 from a transcrip-
tional suppressor to an oncogenic transcriptional activator.
We have studied the activation of the GADD153 promoter
by two chemotherapeutic agents that induce cellular injury
through different mechanisms. In these studies we used
human ovarian carcinoma cells and two drugs that are
important in the treatment of this disease. cDDP is thought
to damage cells by forming adducts in DNA (Pinto and
Lippard, 1985), whereas taxol binds to tubulin and alters its
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1995polymerisation dynamics in a manner that prevents function-
ing of the mitotic spindle (Rowinsky et al., 1993). We wished
to determine whether the activation of this component of the
cellular injury response was mediated by a single mechanism
common to the two types of cellular injury. In this report we
provide evidence that this is not the case, but that cDDP and
taxol mediate activation of the GADD153 promoter and
changes in endogenous GADD153 mRNA levels via different
signal transduction pathways.
Materials and methods
Chemicals
DDP and taxol were obtained from Bristol Myers-Squibb
(Princeton, NJ, USA). Tyrphostin B46 was obtained from
Calbiochem (San Diego, CA, USA) and stored as a 1OmM
stock in dimethyl sulphoxide (DMSO) at - 20°C. Luciferin
was obtained from Analytical Luminescence (San Diego, CA,
USA).
Cell culture
The human ovarian adenoserous carcinoma cell line 2008
(DiSaia et al., 1972) was carried as an exponentially growing
monolayer in a humidified incubator at 37°C and 5% carbon
dioxide in RPMI-1640 supplemented with 5% fetal calf
serum and 2 mM glutamine.
Luciferase assay
pGADD-LUC, a GADDJ53 promoter-driven luciferase
reporter construct was created by ligating the ClaI/HindIII
fragment of p9000 (a gift from Dr NJ Holbrook, NIA, NIH,
Baltimore, MD, USA), containing the hamster GADD153
promoter into the AccI/HindIII site of pB-LUC (Luethy et
al., 1990). pB-LUC contains the firefly luciferase gene ligated
into the BamHI site of pBluescript KS- (a gift from Dr L
Quattrochi).
The cells were transfected with the pGADD-LUC con-
struct by a modification of the method described by Rose et
al. (1991). Cells were plated at 3 x I05 cells per 35 mm dish,
and then 18 h later they were incubated at 37°C with 5 jig of
plasmid DNA and 30 ,l of liposomes in I ml of RPMI-1640.
After 3 h the lipids were removed and the cells were treated
with cDDP for 1 h or taxol for 24 h. Six hours after the end
of cDDP exposure, or after the 24 h taxol exposure, the cells
were lysed in 500 gl of lysis buffer (25 mM glycylglycine, pH
7.8, 15 mM magnesium sulphate, 4 mM EGTA, 1% Triton
X-100, 1 mm dithiothreitol). Luciferase activity was measured
by a modification of the method described by Brasier et al.
(1989). Cell lysate (50gl) was added to 200 tll of reaction
buffer (lysis buffer with 15 mm potassium phosphate, pH 7.8,
and 2 mM ATP added). Light emission was measured after
injection of 100pl of 1 mM luciferin into the lysate/reaction
mixture using a MonoLight 2001 (Analytical Luminescence).
Northern blotting
Total cellular RNA was extracted and Northern blots
prepared using MagnaGraph nylon membranes (MSI, West-
boro, MA, USA) by standard techniques (Davis et al., 1986).
The extent of hybridisation was quantified by the Molecular
Imager System (Bio-Rad, Hercules, CA, USA). The human
GADD153 probe was a gift of Dr NJ Holbrook. Lane
loading differences were corrected for by comparison to the
same blot hybridised with a P-actin probe.
Colonyforming assays and median effect analysis
Three hundred cells were plated per dish and allowed to
attach overnight. The cells were treated with tyrphostin B46
or DMSO for 1 h followed by a 1 h concurrent exposure with
DDP, or a concurrent 24 h exposure to taxol. After DDP
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exposure, tyrphostin B46 or DMSO was added back to the
media for a total exposure of 24 h. After drug exposure, the
media was replaced and at 10 days after treatment, colonies
of 50 cells or more were counted. Median effect analysis was
carried out as described by Chou and Talalay (1986).
Results
Effect oftaxol and cDDP on activation ofthe GADD153
promoter and endogenous GADD153 mRNA
Human ovarian 2008 cells were transiently transfected with
pGADD-LUC, which contains 786 basepairs of the hamster
GADD153 promoter coupled to the luciferase reporter gene.
They were then exposed to taxol for 24 h over a concentra-
tion range corresponding to 1-10 times the IC50, and
luciferase activity was measured 24 h after the start of drug
exposure, which previous work had shown to be the time of
peak luciferase activity (data not shown). Figure la shows
the change in luciferase activity expressed relative to the level
in untreated control cells; and indicates that taxol activated
the GADD153 promoter in a concentration-dependent man-
ner. Figure 1b shows the effect of the same taxol exposure on
the change in endogenous GADD153 mRNA levels in non-
transfected cells determined by Northern blot analysis of
RNA harvested 24 h after the start of drug exposure. Taxol
increased the level of endogenous GADD153 mRNA in a
dose-dependent manner that corresponded well with its effect
on GADD153 promoter activation.
a
a)
a)
CA
35 50
Taxol (nM)
b
z C,, a)
z
E
4n
(9 C,
C',
a,
0 5 10 20 35 50
Taxol (nM)
Figure 1 Effect of taxol on the activation of the GADD153
promoter and on endogenous GADD153 mRNA levels. (a)
Luciferase activity measured in cells transiently transfected with
pGADD-LUC. (b) Fold change in endogenous gaddl53 mRNA
levels quantified by Northern analysis normalised for P-actin
expression. In both types of experiments, measurements were
made 24 h after the start of taxol exposure. Bars represent the
mean of two (b) or three (a) experiments performed with dup-
licate cultures. Vertical bars ± s.e.
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Similar experiments were conducted with cDDP in which
2008 cells were transiently transfected with pGADD-LUC
and exposed to cDDP for 1 h. Maximal levels of luciferase
activity were found to occur at 6 h after the end of a 1 h
drug exposure (data not shown). Figure 2a shows that over
an equitoxic concentration range cDDP caused substantially
less activation of the GADD153 promoter, as reflected by
luciferase activity, than did taxol. However, Figure 2b shows
that cDDP produced up to a 40-fold increase in endogenous
GADD153 mRNA level after drug treatment (note the
difference in the ordinate scale in a and b). Thus, in contrast
to what was observed with taxol, in the case of cDDP there
was a much smaller effect on promter activity than on
endogenous GADD153 level.
Figure 3 shows that there is a good correlation between
the fold change in endogenous mRNA and the fold activa-
tion of the GADDJ53 promoter for cDDP (r = 0.94) and
taxol (r = 0.96). However the slope of the least mean squares
line was 1.1 for taxol as opposed to 29.5 for cDDP. Thus, for
a given degree of activation of the transfected promoter, the
effect on endogenous GADDJ53 mRNA level was 27-fold
greater for cDDP than for taxol. This indicates that the
mechanisms by which the two drugs produce these changes
differ in at least some components.
Figure 4 shows an analysis of the correlation between the
degree of cytotoxicity produced by the drug exposure and the
change in endogenous GADDJ53 mRNA. For both agents
there was an excellent correlation (cDDP, r = 0.98; taxol,
r = 0.97). As cell kill was increased with cDDP there was a
much greater effect on GADDJ53 mRNA levels than when
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cell kill was increased with incrementally higher concentra-
tions of taxol. This indicates that GADD153 mRNA levels
did not vary solely as a function of the degree of toxicity, but
were also a function of the specific drug which caused the cell
death.
Effect oftyrphostin B46 on GADD153 promoter activation
Tyrphostins are inhibitors of tyrosine kinases that were
originally designed to compete for the substrate binding site
of the epidermal growth factor receptor tyrosine kinase.
Gazit et al. (1989, 1991) found that tyrphostin B46 can
inhibit epidermal growth factor-induced proliferation with an
IC50 of 2.5 JiM. We compared the ability of tyrphostin B46 to
alter the taxol and cDDP-induced increase in luciferase
activity following transfection of pGADD-LUC into 2008
cells. After transfection, cells were treated withlOJIM tyr-
phostin B46 for 1 h and then concurrently with 70 nM taxol
and tyrphostin B46 for 24 h. The data presented in Figure 5a
shows that, relative to the vehicle alone control, 1O IM tyr-
phostin B46 had no significant effect on the basal activity of
the pGADD-LUC, nor on the ability of taxol to activate the
GADD153 promoter. In contrast, tyrphostin B46 was able to
inhibit the response elicited by a 1 h exposure to cDDP. As
shown in Figure 5b, 50 JIM DDP induced a 2.6-fold increase
in luciferase activity 6 h after exposure compared with un-
treated controls. Treatment with tyrphostin B46 for 7 h had
cn
>
a)
z cE
E
tl)
a) CE
.a) cc
T
T
0
0
l-1-
0 10 20 30
DDP (gM)
b
z
DE
E
LO
>
a)
Ca)
cc
f(x)= 29.5 x - 26.6
r = 0.94
f(x)= 1.1 x+0.2
r = 0.96
2 3 4 5
Relative luciferase activity
Figure 3 Correlation between drug effect on relative endogenous
m7 GADD153 mRNA levels and relative luciferase activity. For
known doses of drug, endogenous mRNA levels were plotted
relative to luciferase activity. Linear regression curves (linear least
squares method) were plotted using DeltaGraph for the Macin-
tosh software (DeltaPoint, Monterev. CA, USA). *. Taxol: *.
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Figure 2 Effect of cDDP on the activation of the GADD153
promoter and on endogenous GADD153 mRNA levels. (a)
Luciferase activity measured in cells transiently transfected with
pGADD-LUC 6 h after a 1 h treatment with cDDP. (b) Fold
change in endogenous GADDJ53 mRNA levels quantified by
Northern analysis normalised for f-actin expression. Total RNA
was extracted 24 h after a I h cDDP exposure. Bars represent the
mean of two (b) or three (a) experiments performed with dup-
licate cultures. Vertical bars ± s.e.
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Figure 4 Correlation between drug effect on relative endogenous
GADD153 mRNA levels and relative cytotoxicity as measured by
IC50. For known doses of drug, endogenous mRNA levels were
plotted relative to fold IC50. Linear regression curves (linear least
squares method) were plotted using DeltaGraph for the Macin-
tosh software (DeltaPoint). *, Taxol; 0, cDDP.
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no significant effect on the basal activity of the GADD153
promoter. However, tyrphostin B46 significantly inhibited the
cDDP-induced activation of the GADD153 promoter in a
dose-dependent manner, (P = 0.009 at 1 ,iM and P<0.0001
at 10 JiM). Treatment with 1 JIM genistein, another modulator
of tyrosine kinases, had no effect on the ability ofeither taxol
or cDDP to increase luciferase activity (data not shown).
Thus, the signal transduction pathways leading to activation
of the GADD153 promoter by cDDP and taxol differ at least
with respect to the extent of involvement of a tyrphostin
inhibitable kinase.
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Effect oftyrphostin B46 on the toxicity ofcDDP and taxol
In order to investigate the effect of GADD153 promoter
activation on the toxicity of cDDP and taxol in the 2008
cells, we performed colony-forming assays. The cells were
allowed to attach overnight, exposed to 1OJIM tyrphostin B46
for 1 h and then concurrently with cDDP (1 h) or taxol
(24 h). As shown in Figure 6, incubation with 10JIM tyrphos-
tin B46 decreased the IC50 of cisplatin 2.3-fold from 5.0JIM
cDDP to 2.2jaM cDDP (P = 0.013, t-test). Since tyrphostin
B46 is slightly toxic (1OJM is an IC5), one cannot determine
whether the interaction with cDDP is additive, antagonistic
or synergistic simply by subtraction. In order to determine
the nature of this interaction, the toxicity of cDDP and
tyrphostin B46 were investigated using median effect analysis
(Chou and Talalay, 1986). Median effect analysis is a math-
ematically formal method of determining synergy, additivity
or antagonism. If the combination index for the two drugs is
equal to 1, the effect is additive, if the index is above 1 the
effect is antagonistic, and if the combination index is below 1
the effect is synergistic. As shown in Figure 7, the majority of
the combination index curve for cDDP and tyrphostin B46
falls below 1, indicating that the effect of the drugs is syner-
gistic.
Since tyrphostin B46 decreased the activation of the
GADD153 promoter after cDDP exposure and also increased
cDDP cytotoxicity, we investigated the effect of tyrphostin
B46 on the cytotoxicity of taxol, in which tyrphostin had no
effect on the activation of the GADD153 promoter. As shown
in Figure 8, tyrphostin had no significant effect on the
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Figure 5 The effect of tyrphostin B46 on the induction of
GADDJ53 promoter activity by taxol (a) and cDDP (b).
Luciferase activity is expressed relative to untreated control cells.
_, Control treated cells; W1, 70 nM taxol-treated cells (a) or
50 JIM cDDP-treated cells (b) ± s.d. *, P = 0.0009. **, P<0.0001.
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Figure 7 Plot of the combination index as a function of cell kill
for the interaction between cDDP and tyrphostin B46 against the
2008 cell line. Each data point represents the mean of three
experiments performed in triplicate ± s.d.
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Figure 6 The effect of 10 JIM tyrphostin B46 on the cytotoxicity
of cDDP in the 2008 cell line. *, Control treatment; 0, 10 IM
tyrphostin B46. Each data point represents the mean of three
experiments performed in triplicate ± s.d.
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Figure 8 The effect of 10JIM tyrphostin B46 on the cytotoxicity
of taxol in the 2008 cell line. M, control treatment; 0, 10IM
tyrphostin B46. Each data point represents the mean of three
experiments performed in triplicate ± s.d.
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cytotoxicity of taxol. In fact, there is a slight decrease in
cytotoxicity at high concentrations of taxol.
Discussion
The data presented in this report show that the activation of
the GADD153 promoter can occur through at least two
distinct pathways, here defined by cDDP and taxol. There
are three major pieces of evidence to suggest that two path-
ways exist (1) the relationship between activation of the
promoter and increase in endogenous GADD153 RNA is
different for the two drugs; (2) the two drugs also differ in
the relationship between cytotoxicity and change in
endogenous GADD153 RNA levels; (3) the promoter activa-
tion pathways are differentially inhibitable by tyrphostin B46.
The magnitude of the activation of the GADD153 pro-
moter corresponds closely to the change produced in
endogenous mRNA level in response to activation of the
taxol-inducible pathway (slope 1.1), but this relation is quite
different for the pathway activated by cDDP (slope 29.5).
Stated another way, for a given degree of activation of the
transfected GADD153 promoter, cDDP produced a much
greater increase in endogenous GADD153 mRNA than taxol.
The ability of cDDP to activate the transfected GADD153
promoter is rather weak. Based on results obtained with the
promoter construct used in this study, the effect of cDDP on
endogenous GADD153 levels is likely to be mediated by
elements other than those represented by the promoter
elements present in pGADD-LUC. Alternative mechanisms
such as stabilisation of the GADD153 message may also play
an important role in increasing GADD153 mRNA levels in
response to either drug. Jackman et al. (1994) have reported
that DNA-damaging drugs will stabilise GADD153 RNA and
increase mRNA half-life, yet agents that cause cell cycle
arrest (such as serum starvation and prostaglandin A2) do
not increase mRNA half-life. Our results are consistent with
these findings. However, while we cannot exclude the pos-
sibility that increased mRNA stability accounts for the 26-
fold difference between the increase in mRNA levels and
promoter activity after cDDP-treatment, it seems more likely
that the endogenous GADD153 gene contains promoter
elements that are not contained in pGADD-LUC. It is prob-
able that there are other response elements either 5', 3' or
within the introns of GADD153. In the case of GADD45,
another member of the DNA damage-inducible gene family,
a p53-responsive element is known to lie within the third
intron (Kastan et al., 1992; Hollander et al., 1993).
The second piece of evidence indicating that cDDP and
taxol activate GADD153 expression by different mechanisms
comes from the difference in the magnitude of the increase in
GADD153 mRNA produced by equitoxic exposures to the
two drugs. We have shown that equitoxic schedules of
exposure to the same drug produce equal increases in
GADD153 mRNA (Gately et al., 1994). However, equitoxic
exposures to cDDP and taxol produced quite different
changes in the GADD153 message. For example, at an
exposure of twice the IC50 (10JLM for cDDP, 10 nM for
taxol), cDDP increased the GADD153 message levels by
10-fold whereas taxol increased the message level by only
2-fold. The reason for this difference in message increase is
unclear at this time. However, it may indicate that GADD153
mRNA levels are more strongly increased by activation of
the cellular injury response by an agent that directly causes
DNA damage than by an agent that interferes with tubulin
function. Further study is needed to address this question.
The third piece of evidence arguing for multiple pathways
is the fact that activation of the GADDJ53 promoter by taxol
and cDDP is differentially inhibited by the tyrosine kinase
inhibitor tyrphostin B46. To the extent that tyrphostin B46 is
specific for tyrosine kinases, these data establish that such a
kinase participates in the cDDP-inducible but not the taxol-
inducible pathway. The conclusion that the cDDP activation
pathway is different from that utilised by other agents is
supported further by the observations of Luethy and Holb-
rook (1994), who found that tyrosine kinase inhibitors were
also not able to block the increase in GADD153 mRNA
levels produced by methyl methanesulphonate and UV radia-
tion. This suggests that taxol may be triggering the same
pathway as methyl methanesulphonate and UV radiation.
Currently there is no information about which tyrosine
kinase might be playing a role in the cDDP-activated path-
way. Devary et al. (1992) reported that the activation of the
c-jun promoter after UV irradiation was dependent on the
SRC tyrosine kinase pathway. SRC kinase activates the c-jun
promoter by increasing AP-1 activity. This is unlikely to be
the case for GADD153. While the GADD153 promoter con-
tains an AP-1 responsive site, it is not inducible by the
phorbol ester TPA which increases AP-1 activity (Fornace et
al., 1988). This suggests that AP-1 activity is not responsible
for increases in GADD153 promoter activity after damage. In
fact, co-transfection ofpGADD-LUC with plasmids express-
ing c-jun or constitutively active c-src do not increase
luciferase activity measured twenty-four hours after trans-
fection (DP Gately, unpublished data).
The synergistic enhancement of cDDP cytotoxicity by tyr-
phostin B46 indicates that there is a tyrosine kinase activated
by cDDP treatment that functions to protect the cell after
damage. Inhibition of this tyrosine kinase increases cytotox-
icity of cDDP. This kinase is not activated after taxol treat-
ment, therefore inhibition by tyrphostin has no effect on the
cytotoxicity of taxol. One of the downstream effects of this
signal transduction cascade is the activation of the GADD153
promoter. At this point, we cannot determine whether
GADD153 promoter activation is itself protective, or simply
activated by a signalling cascade that also functions to pro-
tect the cell by other mechanisms. Recent evidence reported
by Barone et al. (1994) indicates that GADD153 protein
microinjected into cells causes GI arrest. Thus, GADD153
may play a role in the GI checkpoint mechanism that is
activated by cellular injury. This checkpoint is thought to
allow cells to repair any DNA damage before entering the
next S-phase. Our data fit well with this hypothesis as we
have previously shown that GADD153 mRNA levels cor-
relate with cellular injury as measured using a colony form-
ing assay (Gately et al., 1994). As the degree of damage
increases, the cell should increase the levels of protective
genes (i.e. GADD153). If this increase is blocked (for exam-
ple, by tyrphostin B46), the cell would be expected to be
more sensitive to the injury. In the absence of agents that
block GADD153 promoter activity, increases in GADD153
mRNA levels should still be a good marker of tumour injury.
Treatments that produce cellular injury activate a number
of different pathways that may be involved in the cellular
response to damage (Kramer et al., 1990; Bartlett et al., 1992;
Devary et al., 1992, 1993; Zhan et al., 1993). However, what
role each of these responses plays in cell survival is still
unknown. Our conclusion that there exist multiple pathways
that can influence GADD153 expression is consistent with the
GADD153 promoter being a convergence point for several
independent signal transduction pathways uniquely involved
in the detection of different kinds of cellular injury.
Abbreviations:
cDDP, cisplatin; gadd, growth arrest and DNA damage; IC50, con-
centration required to inhibit colony formation by 50%; TPA, 12-0-
tetradecanoylphorbol-13-acetate; C/EBP, CAAT/enhancer-binding
protein: LAP, liver-enriched transcriptional activator protein.
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